Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …

Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as
the only mutated oncogene tractable for targeted therapy in neuroblastoma. Cells with these …

ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or
explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive …

Three generations of tyrosine kinase inhibitors (TKI) have been approved for anaplastic
lymphoma kinase (ALK) fusion–positive non–small cell lung cancer. However, none address …

Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor,
have been identified in several neoplastic diseases. Rearranged ALK is a driver of …

Introduction MET amplification is a potentially actionable resistance mechanism in ALK-
rearranged (ALK+) lung cancer. Studies describing treatment outcomes of this molecular …

Following the results of the CROWN phase III trial, the third-generation macrocyclic ALK
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …

Methods We performed a narrative review by searching the PubMed and clinicaltrials. gov
databases for articles published in English from August, 2007 until October, 2022 and …

Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent
oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC) …